Mosaic

10 articles about Mosaic

• The Mosaic Company Unveils Mosaic Biosciences™ to Expand Offerings in Plant Health

  8/15/2023

  The Mosaic Company announced the formation of the Mosaic Biosciences™ platform, a global initiative to bring the latest science and innovation to the agriculture market.

• Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Platform

  10/31/2022

  Mosaic ImmunoEngineering, Inc. announced that two research grants totaling $4.3 million from the National Cancer Institute were awarded to the Company's collaborating scientists and their respective academic institutions.

• Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates

  10/12/2021

  Mosaic ImmunoEngineering Inc. today announced that Nicole F. Steinmetz, Ph.D., acting chief scientific officer and co-founder of Mosaic and the director of the UC San Diego Center for Nano-ImmunoEngineering, delivered a Spotlight Presentation at the World Molecular Imaging Congress (WMIC) on Friday, October 8, 2021.

• Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology

  9/27/2021

  - Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots

• Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors

  6/15/2021

  Mosaic ImmunoEngineering Inc. today announced the election of Robert A. Baffi, Ph.D., to Mosaic's Board of Directors.

• Mosaic ImmunoEngineering Inc. Announces Upgrade to OTCQB Venture Market and Upcoming Presentation at the B. Riley Oncology Investor Conference

  1/19/2021

  Mosaic ImmunoEngineering Inc., (the (OTC PINK:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that it will begin trading on the OTCQB; Venture Market as of today, January 19, 2021.

• Mosaic ImmunoEngineering Inc. Provides an Overview of Development Plans for Advancing Its Lead Immuno-Oncology Product Candidate MI-O-101

  12/14/2020

  -Preclinical Data Published in Peer Reviewed Journals Support Advancing the Program into Human Clinical Trials- -Company Plans to Initiate Discussions with Regulatory Agencies in Early 2021 to Review Its Strategy for IND or Equivalent Filing-

• Driving European Drug Discovery With Mosaic

  12/3/2013

• Mosaic to Present at Goldman, Sachs & Co. Forum

  2/8/2011

• Mosaic and Investment Saskatchewan Announce They Are Seeking a Buyer for Saskferco Products Inc.

  6/20/2008